Condyline (Podophyllotoxin)

What is Condyline?

Condyline (podophyllotoxin 0.5% solution) is a prescription topical medicine used to treat external genital warts; any perianal use must be checked against the exact product indication in adults. It is a purified, standardised extract derived from the roots and rhizomes of Podophyllum plants, and belongs to the antimitotic class of wart treatments.

Unlike immune-modifying treatments such as imiquimod (Aldara), which work by stimulating the immune system, Condyline acts directly on wart tissue by inhibiting cell division in HPV-infected keratinocytes, causing the wart cells to die.

How does Condyline work?

Podophyllotoxin exerts its effect through a well-characterised antimitotic mechanism:

• Tubulin binding: Podophyllotoxin binds to the beta subunit of tubulin, the protein that forms microtubules — the structural scaffold required for cell division.
• Mitotic arrest: By preventing microtubule polymerisation, podophyllotoxin arrests dividing cells in metaphase (the stage of cell division where chromosomes align before separation).
• Cell death: Cells arrested in mitosis cannot complete division and undergo necrosis (cell death), leading to destruction of the wart tissue.
• Selective effect: The effect is most pronounced in rapidly dividing cells, such as the HPV-infected keratinocytes that comprise wart tissue.

The result is a progressive destruction and shedding of the wart over the treatment cycles.

Who is Condyline for?

Condyline is indicated for adults with small to moderate-sized external genital warts; any perianal use must be checked against the exact product indication. It is particularly suitable for patients who:

• Have clearly identifiable discrete warts accessible to precise application; the cited Irish product requires direct medical supervision for all female lesions and male lesions over 4 cm²
• Have confirmed or clinically suspected condylomata acuminata following medical assessment
• Are able to apply the treatment accurately and follow the treatment schedule

Condyline is not appropriate for:

• Internal warts: Condyline should not be applied inside the vagina, urethra, rectum, or on mucous membranes where precise control of application is not possible
• Pregnant women: Podophyllotoxin is contraindicated in pregnancy due to potential teratogenicity and systemic absorption risk
• Large wart areas: Large confluent warts may not be suitable for self-applied topical treatment — a doctor should assess alternatives such as cryotherapy or surgical removal

Dosage and application

Product scope: The instructions below refer to Irish Condyline 5 mg/mL cutaneous solution in the cited HPRA document dated 31 May 2021, for warts on the penis or external female genitalia. This adult article does not provide paediatric instructions or establish current Irish or Spanish availability. Use only on a small area and a small number of warts. All female lesions and male lesions over 4 cm² require direct medical supervision.

Treatment cycle: Apply twice daily (morning and evening) for 3 consecutive days, then stop for 4 days. This constitutes one treatment cycle.

Application instructions (as per prescribing guidance):

1. Clean the treatment area and allow to dry thoroughly.
2. Using the applicator provided, apply the solution precisely to the surface of each wart. Avoid contact with surrounding healthy skin.
3. Allow the solution to dry before dressing or resuming normal activity.
4. Wash hands thoroughly after application.
5. Do not apply to broken, inflamed, or irritated skin.
6. Avoid sexual contact while the solution is on the skin.

Application limits: Do not exceed 50 applicator-fulls per treatment with the cited Irish solution. All female lesions and male lesions over 4 cm² require direct medical supervision. Follow the exact product leaflet and the doctor’s instructions; limits for other podophyllotoxin products are not interchangeable.

Side effects

Local reactions are expected and reflect the cytotoxic action of the medicine on wart tissue.

Common side effects

• Burning, stinging, or pain at the application site
• Redness (erythema)
• Erosion or ulceration of treated tissue (seek advice if severe)
• Itching
• Tenderness

Less common side effects

• Blistering at the treatment site
• Inflammation of surrounding skin if the solution spreads beyond the wart
• Pigmentation changes (may be prolonged)

Systemic effects (with excessive use)

• If used on large areas or for extended periods beyond recommended limits, systemic absorption may cause: nausea, vomiting, peripheral neuropathy, and haematological effects. Use must not exceed the recommended dose or area.

Pause treatment if severe local reactions develop and seek medical advice before restarting.

Condyline vs alternative wart treatments

Condyline vs Warticon: Both contain podophyllotoxin and use 3 treatment days followed by 4 rest days, but the maximum number of cycles and application limits depend on the product. The key differences are in concentration (0.5% solution vs 0.15% cream) and formulation. The cream formulation (Warticon) may be gentler on surrounding skin and easier to apply to moist surfaces. A doctor will advise on the most appropriate formulation.

Condyline vs Aldara: These treatments work through entirely different mechanisms. Aldara (imiquimod) stimulates the immune system rather than directly destroying tissue. Some evidence suggests imiquimod may have lower recurrence rates due to its immune-stimulating properties, but onset of action is slower. The choice depends on individual clinical assessment.

Online assessment for Condyline (Podophyllotoxin)

Condyline is a prescription-only medicine (POM) in all EU member states. It cannot legally be dispensed without a valid prescription from a licensed medical professional.

Prescrivia operates as a technology intermediary: we do not prescribe medicines, employ doctors, or sell medicines. Our platform connects patients with independent doctors who can conduct confidential online health assessments.

Availability of an online assessment, prescribing, dispensing and delivery depends on the medicine, country and applicable law. Spain prohibits distance sale of prescription medicines; a catalogue entry or cross-border prescription does not establish a right to delivery. An in-person examination or testing may be required.

The process, where legally and clinically available:

1. Complete a health assessment: Describe the warts (size, location, duration), your sexual health history, and any previous treatments.
2. Doctor review: An independent doctor reviews your assessment. If podophyllotoxin is clinically appropriate, they may issue a prescription.
3. Pharmacy fulfilment: The prescription is sent to a pharmacy partner to assess dispensing and any supply under the applicable country rules.

Important: Prescrivia does not guarantee that a prescription will be issued. All prescribing decisions are made independently by qualified medical professionals.

Important safety information

Do not use Condyline if you:

• Are pregnant or planning to become pregnant
• Are breastfeeding
• Are allergic to podophyllotoxin or any other ingredient
• Have open wounds or significantly inflamed skin in the treatment area

Tell your doctor before using Condyline if you:

• Are immunocompromised (HIV, immunosuppressant therapy)
• Have previously used any other wart treatments
• Are uncertain whether your skin lesions are genital warts — other conditions (including skin cancer) can resemble warts and must be excluded by a doctor

HPV and transmission: Treating visible warts removes the physical lesions but does not eliminate HPV infection. The virus may persist in surrounding skin and can be transmitted to sexual partners even in the absence of visible warts. Barrier contraception (condoms) reduces but does not eliminate transmission risk.

Sources

• Product information / clinical reference 1

Medical information on this page is based on the following sources:

• World Health Organization (WHO). Human papillomavirus (HPV) — Fact sheet. who.int
• von Krogh G, et al. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sexually Transmitted Infections. 2000;76(3):162–168.

The content-edit date does not certify a clinical review. It is provided for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for advice relevant to your individual health circumstances.